Profil
Ofir Moreno worked as a Senior Director-Chemistry at Dendreon Corp.
from 2003 to 2007.
He then worked at MEI Pharma, Inc. from 2010 to 2022, where he held the position of Senior Vice President-Pharmaceutical Sciences from 2019 to 2022.
Moreno holds a doctorate degree from Harvard University and an undergraduate degree from Cornell University.
Anciens postes connus de Ofir Moreno
| Sociétés | Poste | Fin |
|---|---|---|
| MEI PHARMA, INC. | Directeur Technique/Scientifique/R&D | 01/07/2019 |
| DENDREON CORPORATION | Corporate Officer/Principal | 01/11/2007 |
Formation de Ofir Moreno
| Cornell University | Undergraduate Degree |
| Harvard University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| MEI PHARMA, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Dendreon Corp.
 Dendreon Corp. Medical SpecialtiesHealth Technology Dendreon Corp. discovers, develops and commercializes novel products for the treatment of cancer. The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy ACI product candidates designed to stimulate an immune response in a variety of tumor types. It is an exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. Dendreon was founded by Christopher S. Henney, Edgar G. Engleman and Samuel Strober in 1992 and is headquartered in Seattle, WA. | Health Technology |
